NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: TransCode Therapeutics Appoints Jack E. Stover to Board of Directors
TL;DR
TransCode Therapeutics appoints Jack E. Stover to its Board, bringing 30+ years of leadership to advance its RNA oncology pipeline for competitive advantage in cancer treatment.
TransCode Therapeutics appoints Jack E. Stover to its Board and Audit Committee, leveraging his operational and financial expertise to systematically advance RNA-based cancer therapies.
TransCode Therapeutics strengthens its leadership to accelerate development of RNA therapeutics for metastatic cancer, potentially improving treatment outcomes and quality of life for patients.
TransCode Therapeutics adds a veteran life sciences executive to its Board as it develops innovative RNA nanoparticle technology targeting metastatic cancer biomarkers.
Found this article helpful?
Share it with your network and spread the knowledge!
TransCode Therapeutics (NASDAQ: RNAZ) has appointed Jack E. Stover to its Board of Directors, where he will serve on the Audit Committee and Nominating Committee, while Dr. Magda Marquet steps down from the Audit Committee.
Jack E. Stover brings more than 30 years of executive leadership experience across public and private life sciences companies, with a background spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.
He will serve on the Audit Committee and the Nominating Committee of TransCode Therapeutics' Board of Directors.
Mr. Stover is expected to contribute operational, financial, and strategic expertise as TransCode advances its RNA and immuno-oncology pipeline for the treatment of high-risk and advanced cancers.
TransCode is a clinical-stage oncology company focused on treating metastatic disease through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform.
The company's lead therapeutic candidate is TTX-MC138, which focuses on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis.
To view the full press release, visit https://ibn.fm/gQDuo. The latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ.
InvestorWire is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community, offering services including access to wire solutions, article syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions.
Curated from InvestorBrandNetwork (IBN)
